|Alexander Lobo||Stern Investor Relations|
|Dr. Milton Werner||Chief Executive Officer|
|Joseph Frattaroli||Chief Financial Officer|
Greetings, welcome to Inhibikase Therapeutics’ Fourth Quarter Full Year 2021 Financial Results. At this time, all participants are in listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. At this time I'll now turn the conference over to Alexander Lobo with Stern Investor Relations.